{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:02:33Z","timestamp":1772136153049,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 20K17456"],"award-info":[{"award-number":["JP 20K17456"]}]},{"name":"the Ministry of Health, Labour, and Welfare","award":["JPMH20FC1044"],"award-info":[{"award-number":["JPMH20FC1044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Phosphodiesterase (PDE) 4 inhibitors have been reported to suppress the progression of dermal fibrosis in patients with systemic sclerosis (SSc); however, the precise mechanisms remain to be elucidated. Therefore, we conducted experiments focusing on the antifibrotic and anti-inflammatory effects of apremilast using dermal fibroblasts derived from patients with SSc and an SSc mouse model. Dermal fibroblasts derived from healthy controls and patients with SSc were incubated with apremilast in the presence or absence of 10\u00a0ng\/ml transforming growth factor (TGF)-\u03b21 for the measurement of intracellular cAMP levels and evaluation of mRNA and protein expression. A bleomycin-induced dermal fibrosis mouse model was used to evaluate the inhibitory effects of apremilast on the progression of dermal fibrosis. Intracellular cAMP levels were significantly reduced in dermal fibroblasts derived from patients with SSc compared with those derived from healthy controls. Apremilast reduced the mRNA expression of profibrotic markers and the protein expression of type I collagen and Cellular Communication Network Factor 2 (CCN2) in dermal fibroblasts. Additionally, apremilast inhibited the progression of dermal fibrosis in mice, partly by acting on T cells. These results suggest that apremilast may be a potential candidate for treating dermal fibrosis in SSc.<\/jats:p>","DOI":"10.1038\/s41598-023-46737-1","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T06:03:16Z","timestamp":1699423396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model"],"prefix":"10.1038","volume":"13","author":[{"given":"Tomoaki","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tochimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"46737_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton, C. P. & Khanna, D. Systemic sclerosis. Lancet 390, 1685\u20131699 (2017).","journal-title":"Lancet"},{"key":"46737_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/exd.14193","volume":"30","author":"C Dees","year":"2021","unstructured":"Dees, C., Chakraborty, D. & Distler, J. H. W. Cellular and molecular mechanisms in fibrosis. Exp. Dermatol. 30, 121\u2013131 (2021).","journal-title":"Exp. Dermatol."},{"key":"46737_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek, M. & Cottin, V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 383, 958\u2013968 (2020).","journal-title":"N. Engl. J. Med."},{"key":"46737_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1346-8138.2009.00758.x","volume":"37","author":"Y Asano","year":"2010","unstructured":"Asano, Y. Future treatments in systemic sclerosis. J. Dermatol. 37, 54\u201370 (2010).","journal-title":"J. Dermatol."},{"key":"46737_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327\u20131339 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"46737_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1067\/mai.2001.119555","volume":"108","author":"DM Essayan","year":"2001","unstructured":"Essayan, D. M. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671\u2013680 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"46737_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li, H., Zuo, J. & Tang, W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front. Pharmacol. 9, 1048 (2018).","journal-title":"Front. Pharmacol."},{"key":"46737_CR8","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","volume":"78","author":"R Zebda","year":"2018","unstructured":"Zebda, R. & Paller, A. S. Phosphodiesterase 4 inhibitors. J. Am. Acad. Dermatol. 78, S43\u2013S52 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"46737_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0165-6147(99)01307-3","volume":"20","author":"WF Simonds","year":"1999","unstructured":"Simonds, W. F. G protein regulation of adenylate cyclase. Trends Pharmacol. Sci. 20, 66\u201373 (1999).","journal-title":"Trends Pharmacol. Sci."},{"key":"46737_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1476-5381.2012.01847.x","volume":"166","author":"PA Insel","year":"2012","unstructured":"Insel, P. A. et al. cAMP and Epac in the regulation of tissue fibrosis. Br. J. Pharmacol. 166, 447\u2013456 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"46737_CR11","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","volume":"24","author":"LI Sakkas","year":"2017","unstructured":"Sakkas, L. I., Mavropoulos, A. & Bogdanos, D. P. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr. Med. Chem. 24, 3054\u20133067 (2017).","journal-title":"Curr. Med. Chem."},{"key":"46737_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110185","volume":"90","author":"M Ookawara","year":"2022","unstructured":"Ookawara, M. & Nio, Y. Phosphodiesterase 4 inhibitors in diabetic nephropathy. Cell Signal 90, 110185 (2022).","journal-title":"Cell Signal"},{"key":"46737_CR13","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1093\/rheumatology\/keaa249","volume":"59","author":"M Cutolo","year":"2020","unstructured":"Cutolo, M. et al. Apremilast interferes with the TGF\u03b21-induced transition of human skin fibroblasts into profibrotic myofibroblasts: In vitro study. Rheumatol (Oxf) 59, 3927\u20133938 (2020).","journal-title":"Rheumatol (Oxf)"},{"key":"46737_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","volume":"76","author":"C Maier","year":"2017","unstructured":"Maier, C. et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann. Rheum. Dis. 76, 1133\u20131141 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"46737_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41401-021-00656-x","volume":"43","author":"QK Lu","year":"2022","unstructured":"Lu, Q. K. et al. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells. Acta Pharmacol. Sin. 43, 376\u2013386 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"46737_CR16","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi, L. et al. Trial of a Preferential Phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N. Engl. J. Med. 386, 2178\u20132187 (2022).","journal-title":"N. Engl. J. Med."},{"key":"46737_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann. Rheum. Dis. 72, 1747\u20131755 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"46737_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-019-1881-3","volume":"21","author":"T Higuchi","year":"2019","unstructured":"Higuchi, T. et al. Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: Contribution to the novel treatment. Arthritis Res. Ther. 21, 103 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"46737_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2019.11.013","volume":"101","author":"KW Finnson","year":"2020","unstructured":"Finnson, K. W., Almadani, Y. & Philip, A. Non-canonical (non-SMAD2\/3) TGF-\u03b2 signaling in fibrosis: Mechanisms and targets. Sem. Cell Dev. Biol. 101, 115\u2013122. https:\/\/doi.org\/10.1016\/j.semcdb.2019.11.013 (2020).","journal-title":"Sem. Cell Dev. Biol."},{"key":"46737_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1346-8138.2009.00764.x","volume":"37","author":"T Yamamoto","year":"2010","unstructured":"Yamamoto, T. Animal model of systemic sclerosis. J. Dermatol. 37, 26\u201341 (2010).","journal-title":"J. Dermatol."},{"key":"46737_CR21","doi-asserted-by":"publisher","first-page":"15416","DOI":"10.1074\/jbc.M610432200","volume":"282","author":"SA Black","year":"2007","unstructured":"Black, S. A., Palamakumbura, A. H., Stan, M. & Trackman, P. C. Tissue-specific mechanisms for CCN2\/CTGF persistence in fibrotic gingiva: Interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J. Biol. Chem. 282, 15416\u201315429 (2007).","journal-title":"J. Biol. Chem."},{"key":"46737_CR22","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1073\/pnas.0801490105","volume":"105","author":"U Yokoyama","year":"2008","unstructured":"Yokoyama, U. et al. The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc. Natl. Acad. Sci. U S A 105, 6386\u20136391 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"46737_CR23","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1074\/jbc.M212097200","volume":"278","author":"T Hoshino","year":"2003","unstructured":"Hoshino, T. et al. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J. Biol. Chem. 278, 12752\u201312758 (2003).","journal-title":"J. Biol. Chem."},{"key":"46737_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","volume":"10","author":"F Xu","year":"2020","unstructured":"Xu, F., Na, L., Li, Y. & Chen, L. Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 10, 54 (2020).","journal-title":"Cell Biosci."},{"key":"46737_CR25","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1007\/s11010-021-04219-w","volume":"476","author":"W Qin","year":"2021","unstructured":"Qin, W., Cao, L. & Massey, I. Y. Role of PI3K\/Akt signaling pathway in cardiac fibrosis. Mol. Cell Biochem. 476, 4045\u20134059 (2021).","journal-title":"Mol. Cell Biochem."},{"key":"46737_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/ard.2010.134825","volume":"70","author":"A Crilly","year":"2011","unstructured":"Crilly, A. et al. Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Ann. Rheum. Dis. 70, 1130\u20131137 (2011).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46737-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46737-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46737-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T06:12:13Z","timestamp":1699423933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46737-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46737-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2610128\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. In addition, MH received speaker fees from AbbVie Japan GK, AstraZeneca K.K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd., and UCB Japan Co. Ltd. MH is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. The Division of Multidisciplinary Management of Rheumatic Diseases is an endowment department supported by an unrestricted grant from Ayumi Pharmaceutical Corp., Asahi Kasei Corp., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and AbbVie Japan GK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19378"}}